(Source: PRNewswire-FirstCall)
BOSTON, May 29 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation , today announced the launch of a website designed to help investigators apply the new 1.1 version of RECIST (Response Evaluation Criteria In Solid Tumors) in medical imaging-based oncology trials. Perceptive Informatics, which actively participated in the RECIST Working Group, has incorporated into its RECIST website at http://www.recist.com/ a comparison between RECIST 1.0 and 1.1, as well as instructions on how to effectively use the new criteria.
Medical imaging experts from Perceptive Informatics will be available at Booth #1881 during the American Society of Clinical Oncology (ASCO) Annual Meeting, being held today through June 2, 2009 in Orlando, Florida, to discuss application of the new RECIST 1.1 criteria. These experts will address medical, scientific, and regulatory solutions to improve the use of medical imaging as a surrogate endpoint in oncology trials.
"Independent review using RECIST is an essential part of pivotal oncology trials," said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics. "With the release of the RECIST 1.1 toolset Perceptive Informatics maintains a leading position with respect to incorporation of the RECIST criteria into Independent Review Charters for regulatory approval of oncology treatments. Perceptive remains at the forefront of incorporating the new RECIST criteria into medical imaging services to meet immediate demand from clients sponsoring oncology trials."
"Today, the majority of clinical trials evaluating cancer treatments for objective response or progression of disease in solid tumors use RECIST. The new version of RECIST will provide a number of benefits to sponsors including more robust data analysis for patients with certain disease indications as well as the ability to incorporate long-awaited enhancements to evaluate certain types of cancer treatments," said Oliver Bohnsack, M.D., Medical Director of Oncology for Perceptive Informatics.
Perceptive Informatics offers a range of capabilities in the application of imaging techniques from early clinical development through late phase studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology imaging. More information about the Medical Imaging capabilities provided by Perceptive Informatics is available at http://www.perceptive.com/product/imaging/index-medical-imaging.html.
RECIST is a set of published rules that define when cancer patients improve, stay the same, or worsen during treatments.
